$0.03
(Market cap
$27 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
5.4
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-3.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.2
-
Face value
--
-
Shares outstanding
41,119,820
10 Years Aggregate
CFO
$-275.91 Mln
EBITDA
$-403.02 Mln
Net Profit
$-394.49 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BeyondSpring - ADR
| -59.2 | -43.1 | -61.1 | -63.4 | -9.8 | -52.9 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
BeyondSpring - ADR
| 0.0 | -52.1 | -58.5 | -62.9 | -21.3 | -17.3 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
BeyondSpring - ADR
|
0.7 | 27.4 | 0.0 | -6.7 | -- | -- | -- | 5.4 |
| 13.8 | 1,377.3 | 397.5 | 79.0 | -18.3 | -- | 16.5 | 6.4 |
Shareholding Pattern
View DetailsAbout BeyondSpring - ADR
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the... TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey. Read more
-
Co-Founder, Chairman & CEO
Dr. Lan Huang Ph.D.
-
Co-Founder, Chairman & CEO
Dr. Lan Huang Ph.D.
-
Headquarters
Florham Park, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for BeyondSpring - ADR
What is the current share price of BeyondSpring Inc - ADR Today?
The share price of BeyondSpring Inc - ADR is $0.67 (NASDAQ) as of 28-Aug-2026 16:00 EDT. BeyondSpring Inc - ADR has given a return of -9.76% in the last 3 years.
What is the current PB & PE ratio of BeyondSpring Inc - ADR?
Since, TTM earnings of BeyondSpring Inc - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-8.24 |
-2.05 |
2024 |
-5.82 |
-1.97 |
2023 |
-1.67 |
-1.31 |
2022 |
-2.21 |
-12.28 |
2021 |
-2.75 |
8.45 |
What is the 52 Week High and Low of BeyondSpring Inc - ADR?
The 52-week high and low of BeyondSpring Inc - ADR are Rs 2.44 and Rs 0.57 as of 30-Aug-2026.
What is the market cap of BeyondSpring Inc - ADR?
BeyondSpring Inc - ADR has a market capitalisation of $ 27 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in BeyondSpring Inc - ADR?
Before investing in BeyondSpring Inc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.